# Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct06632327/  
OnCo record `nct06632327` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of cisplatin, carboplatin, pemetrexed, gemcitabine and other drugs in lung cancer, run by Alliance for Clinical Trials in Oncology, active but no longer recruiting.

## Summary

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer is a phase 3, randomised interventional study registered as NCT06632327 by Alliance for Clinical Trials in Oncology, with a registry enrolment figure of 37 participants, started 2024-12-11 and due to reach its primary completion in 2029-04-30. Interventions recorded: Surgical Procedure; Cisplatin; Carboplatin; Pemetrexed; Gemcitabine; Docetaxel; Vinorelbine; Nivolumab; Pembrolizumab; Atezolizumab; Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography. Conditions listed: Resectable Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8. Primary outcome: 3-year real-world event-free survival (rwEFS); Overall survival (OS). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed surgically resectable stage IIA to IIIB NSCLC according to the American Joint Committee on Cancer (AJCC) 9th edition (stage IIA to IIIB NSCLC up to single station N2, according to the AJCC 8th edition)". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06632327
- Phase: 3
- Setting: Perioperative Versus Adjuvant Systemic Therapy in Patients With Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG
- Sponsor: Alliance for Clinical Trials in Oncology
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT06632327: https://clinicaltrials.gov/study/NCT06632327

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Vinorelbine](https://onco.cc/drugs/vinorelbine/)
- companies: [Alliance for Clinical Trials in Oncology](https://onco.cc/companies/alliance-oncology/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06632327.json